Exact Sciences Q1 Revenues Tumble as it Awaits FDA Decision | GenomeWeb

NEW YORK (GenomeWeb) – Exact Sciences today announced a year-over-year tumble in its first quarter revenues as it awaits a decision by the US Food and Drug Administration on the company's colorectal cancer screening test.

The Madison, Wis.-based molecular diagnostics firm reported $294,000 in revenues for the three months ended March 31, down 71 percent from $1.0 million for the first quarter in 2013. The figure fell short of the consensus analyst revenue estimate of $600,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.